Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

New Agents

Research into new physical or chemical means to treat disease.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
323Background: Until few years ago, docetaxel (DOC) was the only agent able to significantly prolong overall survival (OS) of… Expand
Is this relevant?
2017
2017
5030Background: Abiraterone acetate (AA), cabazitaxel (CABA), and enzalutamide (ENZ) may prolong survival in mCRPC pts… Expand
Is this relevant?
Review
2016
Review
2016
Hormone receptor positive breast cancer (HR-positive BC) is the most frequent BC subtype (∼70%), with endocrine treatment… Expand
  • figure 2
  • figure 3
  • table 2
  • table 3
  • figure 4
Is this relevant?
Review
2015
Review
2015
BACKGROUND Two new hormonal agents (NHAs), abiraterone and enzalutamide, and one chemotherapeutic agent, cabazitaxel (CABA… Expand
Is this relevant?
2014
2014
The use of new agents (NAs) such as bortezomib, thalidomide, and lenalidomide has extended the survival of patients with multiple… Expand
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Therapy-related acute myeloid leukemia (tAML) is a rare but highly fatal complication of cytotoxic chemotherapy. Despite major… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2012
2012
With the introduction of high-dose therapy and new agents, outcomes of treatment have improved considerably for patients with… Expand
Is this relevant?
Review
1994
Review
1994
In some parts of the world, SCC of the penis represents a significant health problem. Although in the early stages it can be… Expand
Is this relevant?
1991
1991
Fludarabine Monophosphate (FLU) is an adenosine analogue with a high-level of anti-leukemic activity in patients (pts) with CLL… Expand
  • table 2
  • table 1
  • table 3
  • table 4
Is this relevant?
1984
1984
  • David B. Sachar
  • The American journal of gastroenterology
  • 1984
  • Corpus ID: 22468260
Treatment programs for digestive diseases should be evaluated by randomized clinical trials. Under most circumstances, the best… Expand
Is this relevant?